Can B Corp (CANB)

[DarthYoda]

Sorry, one more batch of DD here, but I don't believe Congress intends on going back and forth with the FDA over 100+ of each and every cannabinoid throughout the next millennium. FDA has ZERO IND preclusion in order to do so for secondary cannabinoids anyway. They can't just make one up.

Congress obligated FDA and USDA with regulating hemp when they passed the Farm Bill. However, the FDA said it would take them "at least several years" to be able to do so. Congress told the FDA that timeframe is "unacceptable" and has given the FDA 180 days from December 20th, 2019 to provide a CBD market study to congress that gives the current state of "mislabeling" and "adulteration" in the industry. IMO, it will be very interesting to hear the parameters that the FDA uses to define the two concepts within the CBD/hemp industry, especially "adulteration", as I believe the FDA's presentation on that topic may offer clues, or even industry-wide guidance, for acceptable product development.

Congress is definitely more interested in a cannabinoid industry, and not just a cannabidiol industry.

CBG is the "stem cell" cannabinoid, in that it can turn into most other cannabinoids. So, understanding more about CBG specifically will contribute very much to understanding the whole plant, as well as the entourage effect:

"Senate Committee Calls For Enhanced CBD And CBG Cannabis Compound Research"
September 19, 2019

“Cannabis Research—The Committee believes that cannabidiol [CBD] and cannabigerol [CBG], compounds found in cannabis, may provide beneficial medicinal effects. However, there is insufficient scientific information about the long-term effects of these compounds. Additional, coordinated research on a national scale could help determine the toxicology and medicinal effects of CBD and CBG. The Committee encourages NIH to consider additional investment in studying the medicinal effects and toxicology of CBD and CBG.”

https://timesofcbd.com/senate-committee-calls-for-enhanced-cbd-and-cbg-cannabis-compound-research/

Congress is also directing FDA to “perform a sampling study of the current CBD marketplace to determine the extent to which products are mislabeled or adulterated” and report back to lawmakers within 180 days.
Separately, lawmakers set aside nearly $16.5 million in funding to support the implementation of a domestic hemp program under the 2018 Farm Bill, which legalized the crop and its derivatives.

https://www.marijuanamoment.net/congress-attaches-marijuana-hemp-and-cbd-provisions-to-federal-spending-bills/